StockNews.com started coverage on shares of CASI Pharmaceuticals (NASDAQ:CASI – Free Report) in a report released on Tuesday. The brokerage issued a hold rating on the biotechnology company’s stock.
Separately, HC Wainwright cut their price target on shares of CASI Pharmaceuticals from $12.00 to $6.00 and set a buy rating for the company in a research note on Wednesday, May 15th.
Check Out Our Latest Research Report on CASI Pharmaceuticals
CASI Pharmaceuticals Price Performance
CASI Pharmaceuticals (NASDAQ:CASI – Get Free Report) last released its quarterly earnings results on Tuesday, May 14th. The biotechnology company reported ($0.71) EPS for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.66). CASI Pharmaceuticals had a negative return on equity of 110.11% and a negative net margin of 105.76%. The company had revenue of $3.41 million during the quarter. On average, analysts predict that CASI Pharmaceuticals will post -2.56 EPS for the current fiscal year.
Institutional Investors Weigh In On CASI Pharmaceuticals
A hedge fund recently bought a new stake in CASI Pharmaceuticals stock. Howland Capital Management LLC acquired a new stake in CASI Pharmaceuticals, Inc. (NASDAQ:CASI – Free Report) in the first quarter, according to the company in its most recent disclosure with the SEC. The institutional investor acquired 40,429 shares of the biotechnology company’s stock, valued at approximately $146,000. Howland Capital Management LLC owned approximately 0.30% of CASI Pharmaceuticals as of its most recent filing with the SEC. 22.23% of the stock is currently owned by institutional investors.
About CASI Pharmaceuticals
CASI Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People's Republic of China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma.
See Also
- Five stocks we like better than CASI Pharmaceuticals
- Why Are Stock Sectors Important to Successful Investing?
- Celebrate July 4th with These Red, White, & Blue Chip Stocks
- Industrial Products Stocks Investing
- AbbVie Stock: A Perfect Dip for Investors to Buy
- How to Invest in the FAANG Stocks
- Forget NVIDIA: Super Micro Computer Stock Leads in Momentum
Receive News & Ratings for CASI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CASI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.